Application of monoterpenoids and their derivatives for treatment of neurodegenerative disorders. / Volcho, Konstantin P.; Laev, Sergey S.; Ashraf, Ghulam Md et al.
In: Current Medicinal Chemistry, Vol. 25, No. 39, 01.01.2018, p. 5327-5346.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Application of monoterpenoids and their derivatives for treatment of neurodegenerative disorders
AU - Volcho, Konstantin P.
AU - Laev, Sergey S.
AU - Ashraf, Ghulam Md
AU - Aliev, Gjumrakch
AU - Salakhutdinov, Nariman F.
N1 - Publisher Copyright: © 2018 Bentham Science Publishers.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Neurodegenerative disorders (NDDs) like Alzheimer's disease, Parkinson’s disease and Huntington’s disease are a heterogeneous group of disorders with the progressive and severe loss of neurons. There are no full proof cures for these diseases, and only medicines are available that can alleviate some of the symptoms. Developing effective treatments for the NDDs is a difficult but necessary task. Hence, the investigation of monoterpenoids which modulate targets applicable to many NDDs is highly relevant. Many monoterpenoids have demonstrated promising neuroprotective activity mediated by various systems. It can form the basis for elaboration of agents which will be useful both for the alleviation of symptoms of NDDs and for the treatment of diseases progression and also for prevention of neurodegeneration. The further developments including detections of monoterpenoids and their derivatives with high neuroprotective or neurotrophic activity as well as the results of qualified clinical trials are needed to draw solid conclusions regarding the efficacy of these agents.
AB - Neurodegenerative disorders (NDDs) like Alzheimer's disease, Parkinson’s disease and Huntington’s disease are a heterogeneous group of disorders with the progressive and severe loss of neurons. There are no full proof cures for these diseases, and only medicines are available that can alleviate some of the symptoms. Developing effective treatments for the NDDs is a difficult but necessary task. Hence, the investigation of monoterpenoids which modulate targets applicable to many NDDs is highly relevant. Many monoterpenoids have demonstrated promising neuroprotective activity mediated by various systems. It can form the basis for elaboration of agents which will be useful both for the alleviation of symptoms of NDDs and for the treatment of diseases progression and also for prevention of neurodegeneration. The further developments including detections of monoterpenoids and their derivatives with high neuroprotective or neurotrophic activity as well as the results of qualified clinical trials are needed to draw solid conclusions regarding the efficacy of these agents.
KW - Acetylcholinesterase inhibitors
KW - Alzheimer's disease
KW - Cannabinoids
KW - Huntington’s disease
KW - Monoterpenes
KW - Monoterpenoids
KW - Neuroprotective activity
KW - Parkinson’s disease
KW - Humans
KW - Neuroprotective Agents/chemistry
KW - Brain Ischemia/metabolism
KW - Animals
KW - Neurodegenerative Diseases/drug therapy
KW - Cholinesterase Inhibitors/chemistry
KW - Receptor, Cannabinoid, CB2/antagonists & inhibitors
KW - Monoterpenes/chemistry
KW - Acetylcholinesterase/chemistry
KW - Receptor, Cannabinoid, CB1/antagonists & inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85024861710&partnerID=8YFLogxK
U2 - 10.2174/0929867324666170112101837
DO - 10.2174/0929867324666170112101837
M3 - Review article
C2 - 28079000
AN - SCOPUS:85024861710
VL - 25
SP - 5327
EP - 5346
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 39
ER -
ID: 18067049